Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chongqing Tianhai Medical Equipment Sets Up R&D Base In England At Bargain Price

This article was originally published in PharmAsia News

Executive Summary

Chongqing Tianhai Medical Equipment, a Chinese digital medical equipment producer, has officially set up its R&D base in England. It has engaged two top British executives for R&D and sales, at a fraction of their previous salaries. The move represents Chongqing Tianhai's first step toward mergers or acquisitions of European hi-tech medical device companies. The firm sees the global economic crisis as adversely impacting overseas technology enterprises, but providing the opportunity for China's industry to acquire advanced medical device companies and key talent at bargain prices. Other Chinese hi-tech enterprises are also exploring such ventures; in tandem, relevant government departments in China are establishing measures inclined toward funding and support policies. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071200

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel